Nirmatrelvir/Ritonavir (Paxlovid®). HTA ID: 22014

Assessment Status NCPE assessment ongoing
HTA ID 22014
Drug Nirmatrelvir/Ritonavir
Brand Paxlovid®
Indication Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.  
Assessment Process
Rapid review commissioned 08/03/2022
Rapid review completed 15/03/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Nirmatrelvir/Ritonavir (Paxlovid®) not be considered for reimbursement at the submitted price*.
Full pharmacoeconomic assessment commissioned by HSE 05/05/2023
Pre-submission consultation with Applicant 08/09/2023
Full submission received from Applicant 01/02/2024
Preliminary review sent to Applicant 14/02/2024
NCPE assessment re-commenced 13/03/2024

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.